CN114755409A - 一种定量检测MxA蛋白的免疫荧光层析试剂盒及其制备方法 - Google Patents
一种定量检测MxA蛋白的免疫荧光层析试剂盒及其制备方法 Download PDFInfo
- Publication number
- CN114755409A CN114755409A CN202210456537.3A CN202210456537A CN114755409A CN 114755409 A CN114755409 A CN 114755409A CN 202210456537 A CN202210456537 A CN 202210456537A CN 114755409 A CN114755409 A CN 114755409A
- Authority
- CN
- China
- Prior art keywords
- mxa
- preparation
- immunofluorescence chromatography
- chromatography kit
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000004587 chromatography analysis Methods 0.000 title claims abstract description 32
- 238000010166 immunofluorescence Methods 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000004005 microsphere Substances 0.000 claims abstract description 35
- 239000012528 membrane Substances 0.000 claims abstract description 27
- 238000001514 detection method Methods 0.000 claims abstract description 25
- 238000005507 spraying Methods 0.000 claims abstract description 16
- 238000002156 mixing Methods 0.000 claims abstract description 14
- 230000008878 coupling Effects 0.000 claims abstract description 11
- 238000010168 coupling process Methods 0.000 claims abstract description 11
- 238000005859 coupling reaction Methods 0.000 claims abstract description 11
- 241000287828 Gallus gallus Species 0.000 claims abstract description 9
- 239000000020 Nitrocellulose Substances 0.000 claims abstract description 8
- 229920001220 nitrocellulos Polymers 0.000 claims abstract description 8
- 239000002250 absorbent Substances 0.000 claims abstract description 5
- 230000002745 absorbent Effects 0.000 claims abstract description 5
- 230000003213 activating effect Effects 0.000 claims abstract description 5
- 238000007789 sealing Methods 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 22
- 238000001035 drying Methods 0.000 claims description 18
- 238000009210 therapy by ultrasound Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 6
- 229920002678 cellulose Polymers 0.000 claims description 6
- 239000001913 cellulose Substances 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 239000011521 glass Substances 0.000 claims description 6
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 238000003908 quality control method Methods 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 238000006748 scratching Methods 0.000 claims description 4
- 230000002393 scratching effect Effects 0.000 claims description 4
- 238000002791 soaking Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 239000003761 preservation solution Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 238000007654 immersion Methods 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 description 10
- 239000010931 gold Substances 0.000 description 4
- 229910052737 gold Inorganic materials 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 241000283707 Capra Species 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000001422 normality test Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008593 response to virus Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/551—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6866—Interferon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7156—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种定量检测MxA蛋白的免疫荧光层析试剂盒及其制备方法,由以下步骤组成,荧光微球活化;偶联:抗MxA单克隆抗体或鸡IgY抗体与荧光微球质量比0.1~0.2:1混合偶联,封闭处理、离心,重悬,得到荧光微球标记后的抗MxA单克隆抗体;标记垫喷荧光微球;硝酸纤维素膜喷涂划线;将样品垫、标记垫、硝酸纤维素膜和吸水纸在PVC底板上顺次相互搭接粘贴。本发明制备的定量检测MxA蛋白的免疫荧光层析试剂盒检测灵敏度高,线性范围宽,检测稳定性和重复性优异。
Description
技术领域
本发明属于医学免疫诊断试剂技术领域,具体涉及一种定量检测MxA蛋白的免疫荧光层析试剂盒及其制备方法。
背景技术
MxA是由Ⅰ型干扰素(IFNα/β)诱导人细胞所产生的78kd的抗病毒蛋白,其具有生物活性稳定,抗病毒作用直接、半衰期较长,特异性好,检测方便等优点。人的MxA蛋白分布于细胞的胞浆内,大量研究资料表明,MxA蛋白与病毒的感染密切相关,对病毒反应非常敏感甚至极少的病毒量即可诱导细胞表达MxA蛋白,因此MxA蛋白可用于病毒感染的早期诊断,也可用于临床病毒感染与细菌或者其他微生物感染的鉴别诊断。
目前MxA的临床检测方法有:酶联免疫吸附实验(ELISA)、荧光层析法、胶乳增强免疫比浊法。但是当前检测灵敏度仍然不足,线性范围较窄,开发一种灵敏度高、线性范围广的检测试剂盒是有待解决的技术问题。
发明内容
本部分的目的在于概述本发明的实施例的一些方面以及简要介绍一些较佳实施例。在本部分以及本申请的说明书摘要和发明名称中可能会做些简化或省略以避免使本部分、说明书摘要和发明名称的目的模糊,而这种简化或省略不能用于限制本发明的范围。
本发明提供一种定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法,其由以下步骤组成,
荧光微球活化;
偶联:抗MxA单克隆抗体或鸡IgY抗体与荧光微球质量比0.1~0.2:1混合偶联,封闭处理、离心,重悬,得到荧光微球标记后的抗MxA单克隆抗体;
标记垫喷荧光微球:将浓度为2mg/ml的荧光微球标记后的抗MxA单克隆抗体以2μl/cm喷涂于标记垫,干燥;
硝酸纤维素膜喷涂划线:羊抗鸡二抗划涂为NC膜的质控线,将抗MxA多克隆抗体划涂为NC膜的检测线,干燥;
将样品垫、标记垫、硝酸纤维素膜和吸水纸在PVC底板上顺次相互搭接粘贴。
作为本发明所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法的一种优选方案:所述偶联,抗MxA单克隆抗体与荧光微球质量比为0.125:1,所述抗MxA单克隆抗体,货号为orb167030。
作为本发明所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法的一种优选方案:所述抗MxA多克隆抗体,货号为K107664P。
作为本发明所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法的一种优选方案:所述硝酸纤维素膜喷涂划线,为将浓度为0.5mg/ml的羊抗鸡二抗以1uL/cm的包被量划涂为NC膜的质控线,将浓度为1mg/ml的抗MxA多克隆抗体以1uL/cm的包被量划涂为NC膜的检测线,45℃干燥12小时。
作为本发明所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法的一种优选方案:所述荧光微球活化,为在清洗后的14.7mg荧光微球中加入735ul 50mM MES活化缓冲液,水浴超声处理5min;用蒸馏水配制EDC溶液,EDC溶液浓度为1mg/ml,加入367.5ul的EDC溶液,水浴超声5min,全部混匀,室温放置25min。
作为本发明所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法的一种优选方案:所述偶联,为吸取抗MxA单克隆抗体或者鸡IgY抗体,边振荡边加入到活化后的溶液中;振荡混匀,超声5min,混匀;放入37℃恒温振荡器中,于200r/min反应3h,超声5min。
作为本发明所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法的一种优选方案:所述封闭处理,为取恢复至室温的20%BSA,加入到偶联后的溶液中,混匀,超声5min,于37℃恒温振荡器中,200r/min反应30min;所述离心,为于4℃高速冷冻离心机16000r/min离心30min去上清;所述重悬,为加入保存液重悬;所述保存液,为含有10%BSA和1%TWEEN 20的10mM Tris-HCL缓冲液,pH 7.4。
作为本发明所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法的一种优选方案:所述标记垫,其制备方法为,将玻璃纤维素膜浸入含有10%BSA、4%PVA-10、2%曲拉通100、0.02%Proclin-300的10mM的Tris-HCl缓冲液,pH值为8.0,浸泡时间30min,进行干燥,湿度≤20%,温度37-45℃,干燥10小时。
作为本发明所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法的一种优选方案:所述样品垫,其制备方法为,将玻璃纤维素膜浸入含有10%BSA、5%蔗糖、2%曲拉通100、10mg/mLRBC抗体、0.02%Proclin-300的10mM的PBS缓冲液,pH值为7.2,浸泡时间30min,进行干燥,湿度≤20%,温度37-45℃,干燥10小时。
本发明的有益效果:本发明制备的定量检测MxA蛋白的免疫荧光层析试剂盒,检测灵敏度高,线性范围宽,检测稳定性和重复性优异。
具体实施方式
为使本发明的上述目的、特征和优点能够更加明显易懂,下面结合具体实施例对本发明的具体实施方式做详细的说明。
在下面的描述中阐述了很多具体细节以便于充分理解本发明,但是本发明还可以采用其他不同于在此描述的其它方式来实施,本领域技术人员可以在不违背本发明内涵的情况下做类似推广,因此本发明不受下面公开的具体实施例的限制。
其次,此处所称的“一个实施例”或“实施例”是指可包含于本发明至少一个实现方式中的特定特征、结构或特性。在本说明书中不同地方出现的“在一个实施例中”并非均指同一个实施例,也不是单独的或选择性的与其他实施例互相排斥的实施例。
实施例1:
1、荧光微球标记:
清洗:
(1)检查荧光微球,确保无凝聚、无漂浮物等变质情况,用移液器将荧光微球吹打混匀,于干净的离心管中;荧光微球范围选为0.19-0.21μm,平均粒径为0.2μm,BangsLaboratories,Inc,货号为FCEU002,荧光微球的激发波长为365nm,发射波长为615nm;
(2)加入50mM MES活化缓冲液,于4℃的高速冷冻离心机16000r/min离心、10min,移液器轻轻吸取上清液;
(3)重复步骤(2)。
活化:
(1)在清洗后的14.7mg荧光微球中加入735ul 50mM MES活化缓冲液,水浴超声处理5min。
(2)用蒸馏水配制EDC溶液,EDC溶液浓度为1mg/ml,加入367.5ul的EDC溶液,水浴超声5min,全部混匀,室温放置25min。
偶联:
(1)吸取抗MxA单克隆抗体(购自biorbyt,货号为:orb167030)或者鸡IgY抗体,MxA单克隆抗体或者鸡IgY抗体与荧光微球的质量比为0.125:1,边振荡边加入到上述活化后的离心管中;振荡混匀,超声5min,全部混匀。
(2)放入37℃恒温振荡器中,于200r/min反应3h,超声5min。
封闭:取1.617ml恢复至室温的20%BSA,加入到上述步骤中的离心管中,吹打混匀,超声5min,确保全部混匀。然后于37℃恒温振荡器中,200r/min反应30min。
保存:将上一步处理后的的中间品,于4℃的高速冷冻离心机16000r/min、30min,去上清;加入保存液(10mM Tris-HCL缓冲液,pH 7.4,+10%BSA+1%TWEEN 20),重悬荧光微球。
2、NC膜喷涂划线:
将浓度为0.5mg/ml的羊抗鸡二抗以1uL/cm的包被量划涂为NC膜的质控线,将浓度为1mg/ml的抗MxA多克隆抗体(Beijing Solarbio Science&Technology,货号K107664P)以1uL/cm的包被量划涂为NC膜的检测线,45℃干燥12小时。
3、标记垫的制备:
将标记垫处理液摇匀,标记垫为玻璃纤维素膜,货号为Ahlstrom 8964,标记垫处理液的配方为10mM的Tris-HCl缓冲液(BSA10%,PVA-104%,曲拉通1002%,Proclin-3000.02%),pH值为8.0。
取出标记垫,使用裁纸刀将标记垫裁剪成宽7.8cm,长30cm的尺寸。
将标记垫浸泡在标记垫处理液中,浸泡时间30min,放入干燥间进行干燥10小时,湿度16%,温度40℃。
4、标记垫喷荧光微球:
将荧光微球标记后的MxA单克隆抗体溶液(溶液中MxA单克隆抗体浓度2mg/ml)喷涂于标记垫,使用喷金仪设置喷量:2μl/cm*1次,每条喷金长度30cm,喷金间隔13mm;将已喷金结合垫放到指定网架上,放入干燥间进行干燥,要求至少10小时,湿度≤20%,温度37-45℃。
5、样品垫处理:
样品垫为玻璃纤维素膜,厂家货号为Ahlstrom 8951,裁剪成平整成18mm*300mm尺寸样品垫处理液配方为10mM的PBS缓冲液(BSA10%,蔗糖5%,曲拉通1002%,RBC抗体10mg/mL,Proclin-3000.02%),pH值为7.2,浸泡时间30min,放入干燥间进行干燥10小时,湿度≤20%,温度37-45℃。
试剂盒组装:将样品垫、标记垫、NC膜和吸水纸在PVC底板上顺次相互搭接粘贴,然后裁切成3-4mm宽度的试纸条,压入塑料卡壳,得MxA免疫荧光层析试剂盒。
定量检测MxA蛋白的免疫荧光层析试剂盒检测全血、血清或血浆中MxA的浓度:取50ul全血、血清或者血浆从样品加入区滴加,进行层析反应。15分钟后,使用干式荧光免疫分析仪,测定试纸条检测线和质控线的荧光强度,经过一定的数据拟合计算得到全血、血清或者血浆中MxA的浓度。
针对荧光微球标记检测抗体MxA单克隆抗体和NC膜划线抗体MxA多克隆抗体进行筛选,各抗体信息如下:
测试采用不同抗体组合的MxA检出限和线性范围,结果表明采用单克隆抗体1与多克隆抗体5组合的线性范围最佳,检出限最低,单克隆抗体1与多克隆抗体5组合检出限为0.1ng/mL,线性范围0.1-260ng/mL,单克隆抗体2与多克隆抗体4组合检出限为0.7ng/mL,线性范围1-200ng/mL。
参考区间统计分析:经正态性检验后,如参考值数据近似正态分布或监测数据经变量转换后呈正态分布,采用正态分布法确定参考区间,取单侧上限95%置信区间(平均值x(-)+1.64标准差s)来计算参考区间。
测试240例血清样本:
按照95%置信区间计算参考区间上限(cut off值):
项目 | 例数 | 第95百分位数(第228位数) | 参考区间 |
MxA | 240 | 39.7ng/mL | ≤39.7ng/mL |
实施例1检测试剂盒的重复性测试:
重复性:
分别检测重复性参考品1(MxA蛋白浓度为60±10ng/mL)和重复性参考品2(MxA蛋白浓度为180±40ng/mL),重复检测10次,分别计算检测结果的平均值()、标准差(SD),根据公式得出变异系数(CV)根据式(3)得出变异系数(CV)。
式中:
CV——变异系数;
SD——标准偏差;
批间差:
用3个不同批号试剂盒,分别检测分别检测重复性参考品1(MxA蛋白浓度为60±10ng/mL)和重复性参考品2(MxA蛋白浓度为180±40ng/mL),每个批号分别检测10次,计算检测30次结果的平均值、标准差(SD),根据公式(6)得出变异系数(CV)。
式中:
CV——变异系数;
SD——标准偏差;
重复性结果:
批间差结果:
本发明中,标记垫处理液的配方及pH值、荧光微球的粒径与选择、抗体的选择及抗体与荧光微球的配比均会对检测灵敏度和重复性造成影响,本发明技术方案检测灵敏度高,线性范围宽,检测稳定性和重复性优异。
对照例:
抗体组合采用单克隆抗体3与多克隆抗体4组合的重复性测试结果如下:
抗体组合采用单克隆抗体2与多克隆抗体6组合的重复性测试结果如下:
应说明的是,以上实施例仅用以说明本发明的技术方案而非限制,尽管参照较佳实施例对本发明进行了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的精神和范围,其均应涵盖在本发明的权利要求范围当中。
Claims (10)
1.一种定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法,其特征在于:由以下步骤组成,
荧光微球活化;
偶联:抗MxA单克隆抗体或鸡IgY抗体与荧光微球质量比0.1~0.2:1混合偶联,封闭处理、离心,重悬,得到荧光微球标记后的抗MxA单克隆抗体;
标记垫喷荧光微球:将浓度为2mg/ml的荧光微球标记后的抗MxA单克隆抗体以2μl/cm喷涂于标记垫,干燥;
硝酸纤维素膜喷涂划线:羊抗鸡二抗划涂为NC膜的质控线,将抗MxA多克隆抗体划涂为NC膜的检测线,干燥;
将样品垫、标记垫、硝酸纤维素膜和吸水纸在PVC底板上顺次相互搭接粘贴。
2.根据权利要求1所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法,其特征在于:所述偶联,抗MxA单克隆抗体与荧光微球质量比为0.125:1,所述抗MxA单克隆抗体,货号为orb167030;所述荧光微球,货号为FCEU002。
3.根据权利要求1或2所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法,其特征在于:所述抗MxA多克隆抗体,货号为K107664P。
4.根据权利要求1或2所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法,其特征在于:所述硝酸纤维素膜喷涂划线,为将浓度为0.5mg/ml的羊抗鸡二抗以1uL/cm的包被量划涂为NC膜的质控线,将浓度为1mg/ml的抗MxA多克隆抗体以1uL/cm的包被量划涂为NC膜的检测线,45℃干燥12小时。
5.根据权利要求1或2所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法,其特征在于:所述荧光微球活化,为在清洗后的14.7mg荧光微球中加入735ul 50 mM MES活化缓冲液,水浴超声处理5min;用蒸馏水配制EDC溶液,EDC溶液浓度为1mg/ml,加入367.5ul的EDC溶液,水浴超声5min,全部混匀,室温放置25min。
6.根据权利要求5所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法,其特征在于:所述偶联,为吸取抗MxA单克隆抗体或者鸡IgY抗体,边振荡边加入到活化后的溶液中;振荡混匀,超声5min,混匀;放入 37 ℃恒温振荡器中,于 200 r/min 反应3h,超声5min。
7.根据权利要求6所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法,其特征在于:所述封闭处理,为取恢复至室温的20% BSA,加入到偶联后的溶液中,混匀,超声5min,于 37 ℃恒温振荡器中,200 r/min反应30 min;所述离心,为于4 ℃高速冷冻离心机16000 r/min离心30 min去上清;所述重悬,为加入保存液重悬;所述保存液,为含有10%BSA和1%TWEEN 20的10mM Tris-HCL缓冲液,pH 7.4。
8.根据权利要求1所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法,其特征在于:所述标记垫,其制备方法为,将玻璃纤维素膜浸入含有10% BSA、4% PVA-10、2%曲拉通100、0.02% Proclin-300的10mM的Tris-HCl缓冲液,pH值为8.0,浸泡时间30min,进行干燥,湿度≤20%,温度37-45℃,干燥10小时。
9.根据权利要求1所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法,其特征在于:所述样品垫,其制备方法为,将玻璃纤维素膜浸入含有10% BSA、5%蔗糖、2%曲拉通100、10mg/mLRBC抗体、0.02% Proclin-300的10mM的PBS缓冲液,pH值为7.2,浸泡时间30min,进行干燥,湿度≤20%,温度37-45℃,干燥10小时。
10.权利要求1所述的定量检测MxA蛋白的免疫荧光层析试剂盒的制备方法得到的免疫荧光层析试剂盒,其特征在于:所述免疫荧光层析试剂盒检测样本为人血液样本。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210456537.3A CN114755409A (zh) | 2022-04-27 | 2022-04-27 | 一种定量检测MxA蛋白的免疫荧光层析试剂盒及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210456537.3A CN114755409A (zh) | 2022-04-27 | 2022-04-27 | 一种定量检测MxA蛋白的免疫荧光层析试剂盒及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114755409A true CN114755409A (zh) | 2022-07-15 |
Family
ID=82332834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210456537.3A Withdrawn CN114755409A (zh) | 2022-04-27 | 2022-04-27 | 一种定量检测MxA蛋白的免疫荧光层析试剂盒及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114755409A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116063536A (zh) * | 2022-10-24 | 2023-05-05 | 河北科医生物技术有限公司 | 抗人MxA单克隆抗体及其制备方法和应用 |
CN118209729A (zh) * | 2024-05-16 | 2024-06-18 | 南京立顶医疗科技有限公司 | 一种定量检测MxA的免疫荧光层析试纸条和制备方法 |
-
2022
- 2022-04-27 CN CN202210456537.3A patent/CN114755409A/zh not_active Withdrawn
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116063536A (zh) * | 2022-10-24 | 2023-05-05 | 河北科医生物技术有限公司 | 抗人MxA单克隆抗体及其制备方法和应用 |
CN118209729A (zh) * | 2024-05-16 | 2024-06-18 | 南京立顶医疗科技有限公司 | 一种定量检测MxA的免疫荧光层析试纸条和制备方法 |
CN118209729B (zh) * | 2024-05-16 | 2024-08-27 | 南京立顶医疗科技有限公司 | 一种定量检测MxA的免疫荧光层析试纸条和制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114755409A (zh) | 一种定量检测MxA蛋白的免疫荧光层析试剂盒及其制备方法 | |
JPH02176466A (ja) | 液性試料中の特定物質の測定方法および測定器具 | |
JP5767362B1 (ja) | 免疫クロマト分析装置、免疫クロマト分析方法及び免疫クロマト分析キット | |
CN105785030A (zh) | 一种血清特异性IgE光激化学发光免疫分析试剂盒 | |
CN101377506A (zh) | 磷脂酰肌醇蛋白聚糖-3化学发光免疫分析测定试剂盒及其制备方法 | |
US5155024A (en) | Binder composition and analytical element having stabilized peroxidase in layer containing the composition | |
CN108398565A (zh) | 用于检测犬c-反应蛋白的免疫荧光层析检测卡与制备方法 | |
CN101368969A (zh) | Ⅳ型胶原蛋白化学发光免疫分析定量测定试剂盒及其制备方法 | |
CN113804896A (zh) | 测定人体血清中白介素-8含量的磁微粒化学发光试剂盒 | |
CN112326973A (zh) | 一种用于检测新型冠状病毒抗体的试剂盒及其应用 | |
CN112485443A (zh) | 一种灵敏度高的抗Ro52抗体检测试剂盒 | |
CN115060888A (zh) | 一种新型冠状病毒核衣壳蛋白抗原检测试纸的制备方法 | |
CN114216897A (zh) | 一种sST2化学发光检测试剂盒及其检测方法 | |
CN111239404B (zh) | 一种可以同时检测尿样本和血清样本中的视黄醇结合蛋白的检测试剂盒 | |
CN116027025A (zh) | 一种总甲状腺素荧光免疫层析检测试剂盒及其制备方法 | |
CN109975538A (zh) | 一种检测牛结核病IFN-γ和牛副结核病抗体的试纸条及其制备方法 | |
CN110632294A (zh) | 一种快速检测样品中镉含量的试剂盒 | |
JPS63501819A (ja) | イムノアッセイ法およびキット | |
CN115963256A (zh) | 一种癌胚抗原荧光免疫层析检测试剂盒及其制备方法 | |
CN116068166A (zh) | 一种胶体金保存液及其应用 | |
CN109212195A (zh) | 一种利用磁微粒化学发光法快速检测人amh的试剂盒 | |
CN106918707B (zh) | 一种检测细胞粘附分子的抗体芯片试剂盒 | |
CN116413444A (zh) | 一种检测总三碘甲状腺原氨酸含量的试剂盒及其检测方法 | |
CN111239411A (zh) | 肺炎支原体抗体IgG的免疫检测试剂盒、其制备方法及使用方法 | |
CN115980331B (zh) | 一种检测肝素结合蛋白的试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20220715 |